Chemotherapy

Chemotherapy related articles.

February 7, 2024

Unlocking the Potential of Enhertu: A Revolutionary Advance in Targeted Cancer Therapy

The development of Enhertu represents a significant advancement in targeted cancer therapy, offering new hope for patients with limited treatment options. Enhertu, also known as trastuzumab deruxtecan, is an innovative antibody-drug conjugate (ADC) designed to target HER2-positive cancers, which are associated with aggressive growth and poor prognosis in various cancer types, including breast and gastric cancers
January 22, 2024

Pluvicto: Most Asked Questions

"for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy."
January 19, 2024

Why Atezolizumab and Chemotherapy Should Be Used with Caution in Real-World SCLC Population

Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown promising results in clinical trials when combined with chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, a real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with ES-SCLC in Canada raises important considerations regarding its use.
June 28, 2023

What are the top side effects of Ponatinib

Ponatinib is a medication that is used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) when other treatments have not been effective. Like all medications, Ponatinib has potential side effects. Here are some of the most common ones:
January 15, 2021

3 Highlights about Ovarian Cancer: Options and Risks

This is an important thing that's our patients are worried about this. And this is something that we, as a group need to ask ourselves, how can we improve our adherence? and how to deal with ovarian cancer: options and risks
3 Highlights about Ovarian Cancer: Options and Risks
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more